Progress report on access to hepatitis C treatment
Increased access to highly effective direct-acting antivirals (DAAs) for the treatment of infection
with the hepatitis C virus (HCV) is revolutionizing the prospect of ending HCV epidemics.
Globally, the number of people who initiated DAA-based treatment for HCV rose between
2015 and 2016, from approximately 1 million to 1.5 million.